• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Avanos Medical Inc.

    6/2/25 11:36:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care
    Get the next $AVNS alert in real time by email
    SD 1 avns2024formsd.htm FORM SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    FORM SD
    Specialized Disclosure Report

    AVANOS MEDICAL, INC.
    (Exact name of registrant as specified in its charter)
    Delaware001-3644046-4987888
    (State or other jurisdiction of
    incorporation)
    (Commission File Number)(I.R.S. Employer Identification No.)
    5405 Windward Parkway
    Suite 100 South
    Alpharetta, Georgia
    30004
    (Address of principal executive offices)(Zip Code)
    Jason M. Pickett
    Vice President - Interim Chief Financial Officer
    (844) 428-2667
    (Name and telephone number, including area code, of the person to contact in connection with this report)


    Check the appropriate box to indicate the rule pursuant to which this form is being filed:
    x Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.
    ☐ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended _____________________.




    SECTION 1 - Conflict Minerals Disclosure
    Item 1.01    Conflict Minerals Disclosure and Report
    This Specialized Disclosure Report on Form SD (this "Form SD") by Avanos Medical, Inc. is for the period from January 1, 2024 to December 31, 2024. Unless the context otherwise indicates, the terms “Avanos,” the “Company,” “we,” “us” and “our” refer to Avanos Medical, Inc. and its consolidated subsidiaries.
    During 2024, certain of our operations manufactured, or contracted to manufacture, products for which 3TGs, as defined below, are necessary to their functionality or production (“Covered Products”). Conflict minerals are defined in Section 13(p) of the Securities Exchange Act of 1934, as amended, as (A) cassiterite, columbite-tantalite (coltan), gold, wolframite, and their derivatives, which are limited to tin, tantalum and tungsten (together with gold collectively referred to as “3TGs”), or (B) any other mineral or its derivatives determined by the Secretary of State to be financing conflict in the Democratic Republic of Congo (“DRC”) or any adjoining country that shares an internationally recognized border with the DRC. Accordingly, we have conducted a reasonable country of origin inquiry (“RCOI”) that was designed to determine whether any of the 3TGs in our Covered Products originated in the DRC or an adjoining country (Angola, Burundi, the Central African Republic, the Republic of the Congo, Rwanda, South Sudan, Tanzania, Uganda or Zambia), or were from recycled or scrap sources.
    A summary of our RCOI, as well as the steps taken to exercise due diligence on the source and chain of custody of any 3TGs in our Covered Products, is included in our Conflict Minerals Report (the “Report”), which is filed as Exhibit 1.01 to this Form SD. In addition, our Report and Form SD is publicly available on our website in the Investors section, under Financial Information, at: https://avanos.investorroom.com.
    Forward-Looking Statements
    This Form SD contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including those that express a belief, expectation or intention, including statements relating to our compliance efforts and expected actions. The words “expects,” “intends,” “plans,” “believes,” “anticipates” and similar expressions generally indicate forward-looking statements. These statements are not guarantees of future actions or performance and are subject to various risks, uncertainties and assumptions. Future actions or performance may differ materially from those in the forward-looking statements. Undue reliance should not be placed on these statements, which are only effective as of the date of this Form SD, and the Company undertakes no obligation to publicly update or revise any forward-looking statement.
    Item 1.02    Exhibit.
    Our Conflict Minerals Report for the year ended December 31, 2024 is attached as Exhibit 1.01 to this Form SD.
    Item 2.01    Exhibits.
    Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01. and 1.02 of Form SD.



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     
        
     AVANOS MEDICAL, INC.
      
       
    DATE: June 2, 2025By: /s/ Jason M. Pickett
       Jason M. Pickett
    Vice President and Interim Chief Financial Officer




    EXHIBIT INDEX
    Exhibit
    Number
    Description
    1.01
    Conflict Minerals Report for the year ended December 31, 2024 as required by Items 1.01 and 1.02 of this Form.


    Get the next $AVNS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVNS

    DatePrice TargetRatingAnalyst
    7/25/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    5/22/2023$31.00Buy
    CL King
    2/24/2022$47.00 → $41.00Overweight
    Keybanc
    1/7/2022$37.00 → $36.00Underweight
    Morgan Stanley
    8/4/2021$45.00 → $41.00Underweight
    Morgan Stanley
    8/4/2021$60.00 → $45.00Overweight → Equal-Weight
    Stephens
    8/4/2021$55.00 → $47.00Overweight
    Keybanc
    More analyst ratings

    $AVNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avanos Medical Inc.

      SC 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)

      11/14/24 1:28:34 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

      SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

      2/14/24 11:41:02 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

      SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

      2/13/24 4:58:57 PM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    SEC Filings

    See more
    • SEC Form SD filed by Avanos Medical Inc.

      SD - AVANOS MEDICAL, INC. (0001606498) (Filer)

      6/2/25 11:36:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Avanos Medical Inc.

      10-Q - AVANOS MEDICAL, INC. (0001606498) (Filer)

      5/6/25 4:17:36 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)

      5/6/25 7:07:11 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Leadership Updates

    Live Leadership Updates

    See more
    • Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer

      ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this capacity, he played a pivotal role in driving strategic growth and operational excellence while leading the marketing, sales, service, and support

      3/17/25 7:30:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. Appoints Indrani Franchini to Board of Directors

      ALPHARETTA, Ga., July 1, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Indrani Franchini has been appointed as a new independent member of the Avanos board of directors. "We are excited to welcome Indrani Franchini to the Avanos board," remarked Gary Blackford, Avanos board chair. "Her experience with a broad range of global companies will be invaluable to Avanos as we pursue our vision of getting patients back to the things that matter." "Avanos is committed to addressing some of today's most important healthcare needs and I am thrilled to join it

      7/1/24 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. Appoints Sig Delgado as Senior Vice President, Integrated Supply Chain

      ALPHARETTA, Ga., May 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Sigfrido (Sig) Delgado has been appointed senior vice president, integrated supply chain. In this role, Delgado will lead the teams focused on implementing continuous improvements within the Company's end-to-end supply chain capabilities worldwide. Delgado joins Avanos from Jabil Healthcare, the industry's largest global provider of healthcare manufacturing solutions, where he most recently served as vice president of its global medical technology business. His background includ

      5/13/24 7:15:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AVNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AVNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $AVNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Shimer Julie Ann bought $9,925 worth of shares (500 units at $19.85), increasing direct ownership by 1% to 50,090 units (SEC Form 4)

      4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      3/11/24 5:15:37 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Former Interim CEO Greiner Michael covered exercise/tax liability with 24,245 shares, decreasing direct ownership by 11% to 200,019 units (SEC Form 4)

      4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      5/14/25 2:28:49 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • New insider Pickett Jason Marc claimed ownership of 40,113 shares (SEC Form 3)

      3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      4/29/25 3:45:04 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Amendment: New insider Pacitti David claimed ownership of 242,047 shares (SEC Form 3)

      3/A - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      4/24/25 5:00:37 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Avanos Medical from Overweight to Sector Weight

      7/25/23 6:15:12 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • CL King initiated coverage on Avanos Medical with a new price target

      CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00

      5/22/23 8:52:10 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Keybanc reiterated coverage on Avanos Medical with a new price target

      Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $41.00 from $47.00 previously

      2/24/22 4:48:01 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. Announces First Quarter 2025 Results

      ALPHARETTA, Ga., May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2025 financial results. "In my first couple of weeks at Avanos, I've noticed that the transformation efforts made around the portfolio, the organizational structure and cost management have positioned us well to accelerate our growth profile," said David Pacitti, Avanos's recently appointed Chief Executive Officer. Pacitti continued, "I really like the energy and strategic focus we have right now, which can be leveraged for more consistent execution, to identify more go-t

      5/6/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2025 Financial Results

      ALPHARETTA, Ga., April 28, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Dave Pacitti, chief executive officer, Jason Pickett, interim chief financial officer, Scott Galovan, senior vice president, strategy and corporate development, and Gary Blackford, Avanos board chairman. To instantly jo

      4/28/25 7:47:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Expands Direct Operations for MIC-KEY* Enteral Feeding Products in the UK starting July 2025

      ZAVENTEM, Belgium, April 2, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) a global medical technology company, today announced that it will take direct responsibility for the sales and distribution of its MIC-KEY enteral feeding products in the United Kingdom, effective 25 July 2025. This strategic move reflects Avanos' commitment to prioritizing customer needs, enhancing product availability into the future, and providing a seamless experience for healthcare providers and patients. For the past 29 years, Vygon UK, a leading supplier of surgical and medical devices has

      4/2/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Financials

    Live finance-specific insights

    See more
    • Avanos Medical, Inc. Announces First Quarter 2025 Results

      ALPHARETTA, Ga., May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2025 financial results. "In my first couple of weeks at Avanos, I've noticed that the transformation efforts made around the portfolio, the organizational structure and cost management have positioned us well to accelerate our growth profile," said David Pacitti, Avanos's recently appointed Chief Executive Officer. Pacitti continued, "I really like the energy and strategic focus we have right now, which can be leveraged for more consistent execution, to identify more go-t

      5/6/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2025 Financial Results

      ALPHARETTA, Ga., April 28, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Dave Pacitti, chief executive officer, Jason Pickett, interim chief financial officer, Scott Galovan, senior vice president, strategy and corporate development, and Gary Blackford, Avanos board chairman. To instantly jo

      4/28/25 7:47:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2024 Results

      ALPHARETTA, Ga., Feb. 26, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported fourth quarter and full-year 2024 results. "We are pleased with our fourth quarter results, which delivered 5% organic growth and continued execution on each of our transformation initiative priorities," said Michael Greiner, Avanos's interim chief executive officer. Greiner continued, "For the full year, we generated $83 million of free cash flow and $108 million of adjusted EBITDA. We currently have net debt of approximately $20 million. We believe our strong financial position wil

      2/26/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care